Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
